Lartesertib - Merck KGaA
Alternative Names: M-4076Latest Information Update: 12 Aug 2024
At a glance
- Originator Merck KGaA
- Class Antineoplastics; Radiation-sensitising agents
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Solid tumours
Most Recent Events
- 05 Aug 2024 Phase-II clinical trials in Fallopian tube cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06433219)
- 05 Aug 2024 Phase-II clinical trials in Ovarian cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06433219)
- 05 Aug 2024 Phase-II clinical trials in Peritoneal cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06433219)